We use two types of IV solutions
Streamline Your Workflow From Case Submission to Delivery
These findings suggest that AOMs like tirzepatide and semaglutide could represent a breakthrough in treating obesity-related OSA, potentially offering an effective approach for management when combined with positive airway pressure (PAP) therapy
Hers includes a medical evaluation as part of the enrollment process to determine which medications and treatment plans are suitable for each individual
The new playbook involves: Complex generics : Injectables, respiratory/nasal sprays, ophthalmic, transdermal products with technical barriers that limit competition Controlled substances : A sub-theme gaining momentum at Strides through its Chestnut Ridge facility and DEA quota Biosimilars : The next major wave is pembrolizumab, bevacizumab, ranibizumab, trastuzumab 505(b)(2) specialty: Branded differentiated products filed through the 505(b)(2) pathway (Alembics PIVYA) Peptides: Semaglutide filings by Zydus and Lupin as the frontier opportunity 17) Lupin US - $1.3 Billion and Still Accelerating FY26 US : ~$1.3 Bn (+~40% YoY) | Q4 US: 33,987 Mn ($371 Mn, +55% YoY) Lupins US performance is the headline story of Q4 FY26
Here is Tirzapetides recommended dosing schedule: Week 1-4: 2.5 mg weekly Week 5-8: 5 mg once weekly Week 9-12: 7.5 mg once weekly Week 13-16: 10 mg once weekly Week 17-20: 12.5 mg once weekly Week 21+: 15 mg once weekly (maximum dose) Please keep in mind that this is a recommendation
